$HOOK News

HOOKIPA Pharma Announces Completion of Sale of Oncology Assets to NeoTrail Therapeutics

HOOKIPA Pharma Announces Sale of Oncology Assets to NeoTrail Therapeutics

Trading Halt: Halt status updated at 4:30:00 PM ET: Quotation Resumption: News and Resumption Times

Trading Halt: Halt status updated at 4:30:00 PM ET: Quotation Resumption: News and Resumption Times

HOOKIPA Pharma To Voluntarily Delist And Deregister

Trading Halt: Halted at 4:01:00 p.m. ET - Trading Halt: Halt News Pending

HOOKIPA Pharma Q1 EPS $(1.23) Misses $(0.62) Estimate, Sales $2.00M Miss $3.38M Estimate

HOOKIPA Pharma Inc. (“HOOKIPA”) Statement regarding potential combination for Poolbeg Pharma plc (“Poolbeg”)

Hookipa Pharma announces enrollment completion of Phase 1b HB-500 trial

HOOKIPA Pharma Announces Enrollment Completion of Phase 1b Clinical Trial Evaluating HB-500 for the Treatment of HIV

Poolbeg Pharma plc (“Poolbeg”) and HOOKIPA Pharma Inc. (“HOOKIPA”) Update on Potential Combination of Poolbeg and HOOKIPA

HOOKIPA Pharma Inc - FORM 8 (OPD)

HOOKIPA Pharma Announces Notice to Shareholders Regarding U.K. Disclosure Requirements

HOOKIPA Pharma Inc. (“HOOKIPA”) Rule 2.9 Announcement – Amendment

Hookipa Pharma, Poolberg Pharma in Discussions for All-Stock Merger

Poolbeg Pharma plc (“Poolbeg” or the “Company”) Combination of Poolbeg and HOOKIPA Pharma Inc.

Hookipa Pharma price target lowered to $7 from $24 at JMP Securities

Hookipa Pharma announces workforce reduction of 80%, pause of eseba-vec program

Companies Like HOOKIPA Pharma (NASDAQ:HOOK) Could Be Quite Risky

HOOKIPA Pharma Third Quarter 2024 Earnings: EPS Beats Expectations, Revenues Lag